Back to Journals » ClinicoEconomics and Outcomes Research » Volume 4

Burden of Crohn’s disease: economics and quality of life aspects in Italy

Authors Benedini V, Nicola Caporaso, Corazza G, Rossi Z, Fornaciari G, Cottone M, Frosini G, Mauro C, Chiara O, Colombo G

Received 22 February 2012

Accepted for publication 17 April 2012

Published 24 July 2012 Volume 2012:4 Pages 209—218

DOI https://doi.org/10.2147/CEOR.S31114

Review by Single-blind

Peer reviewer comments 3

Viviano Benedini,1 Nicola Caporaso,2 Gino Roberto Corazza,3 Zaccaria Rossi,4 Giovanni Fornaciari,5 Mario Cottone,6 Giorgio Frosini,7 Mauro Caruggi,8 Chiara Ottolini,8 Giorgio L Colombo9,10
On behalf of the COSMO Study Group

1Department of Gastroenterology, AO Carlo Poma, Mantova; 2Department of Gastroenterology, University of Naples, Federico II, Naples; 3IRCCS Policlinico San Matteo, Pavia; 4Department of Gastroenterology, Ospedale Regina Apostolorum, Albano Laziale, Rome; 5Department of Gastroenterology, Arcispedale S Maria Nuova, Reggio Emilia; 6Medical Division, Azienda Ospedaliera Cervello, Palermo; 7Department of Gastroenterology, Policlinico Universitario Senese, Siena; 8Hospital S Antonio Abate, Gallarate, Varese, 9University of Pavia; School of Pharmacy, Pavia, Lombardy; 10Studi Analisi Valutazioni Economiche (SAVE), Milan, Italy

Background: This was a prospective observational study designed to evaluate direct and indirect costs and quality of life for patients with Crohn’s disease in Italy from the perspectives of the National Health System and of society.
Methods: A total of 162 male and female subjects aged 18–70 years with Crohn’s disease in the active phase and a Crohn’s Disease Activity Index score ≥150 were included in the study. Subjects were recruited from 25 Italian centers on a consecutive basis. The study consisted of four visits undertaken every 6 months with a follow-up period of 18 months. The study started on September 1, 2006 and was completed on April 12, 2010. Multivariate analyses were carried out on demographic characteristics, treatment costs based on the prescribed daily dose, resource use and other cost parameters, and changes in quality of life using the EQ5D questionnaire.
Results: Cost of illness per subject with Crohn’s disease in Italy was estimated to be €15,521 per year, with direct costs representing 76% of total costs. Nonhealth care costs and loss of productivity accounted for 24% of total costs. Societal costs during the first months of enrolment were higher compared with costs in the final months of the study. Quality of life measured by the EQ-5D was 0.558 initially and then increased to 0.739, with a mean value of 0.677 during the enrolment period. The cost of illness was not correlated with age or gender.
Conclusion: The cost of illness was correlated with quality of life; Crohn’s disease had a negative impact on subjects’ quality of life, and higher costs corresponded to a lower quality of life as measured with the EQ5D. Drug treatment may improve quality of life and reduce hospitalization costs. Our results appear to be in line with the results of other international cost-of-illness studies.

Keywords: Crohn’s disease, quality of life, EuroQol, EQ5D, cost-of-illness, cost analysis, economic evaluation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers

Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G

Therapeutics and Clinical Risk Management 2015, 11:1603-1612

Published Date: 19 October 2015

Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation

Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C

Patient Related Outcome Measures 2015, 6:53-60

Published Date: 17 February 2015

Economic and outcomes consequences of TachoSil®: a systematic review

Colombo GL, Bettoni D, Di Matteo S, Grumi C, Molon C, Spinelli D, Mauro G, Tarozzo A, Bruno GM

Vascular Health and Risk Management 2014, 10:569-576

Published Date: 10 September 2014

Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines

Colombo GL, Matteo SD, Antinori A, Medaglia M, Murachelli S, Rizzardini G

ClinicoEconomics and Outcomes Research 2013, 5:489-496

Published Date: 3 October 2013

A cost-of-illness study of spina bifida in Italy

Colombo GL, Di Matteo S, Vinci M, Gatti C, Pascali MP, De Gennaro M, Macrellino E, Mosiello G, Redaelli T, Schioppa F, Dieci C

ClinicoEconomics and Outcomes Research 2013, 5:309-316

Published Date: 2 July 2013

Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy

Ruggeri I, Bragato D, Colombo GL, Valla E, Di Matteo S

ClinicoEconomics and Outcomes Research 2012, 4:375-382

Published Date: 5 December 2012

Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy

Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL

Therapeutics and Clinical Risk Management 2012, 8:377-384

Published Date: 17 September 2012

Antidiabetic therapy in real practice: indicators for adherence and treatment cost

Colombo GL, Rossi E, De Rosa M, Benedetto D, Gaddi AV

Patient Preference and Adherence 2012, 6:653-661

Published Date: 14 September 2012

Cost-effectiveness analysis of initial HIV treatment under Italian guidelines

Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P

ClinicoEconomics and Outcomes Research 2011, 3:197-205

Published Date: 31 October 2011

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

Giorgio L Colombo, Sergio Di Matteo, Maria Elisa Mancuso, et al

ClinicoEconomics and Outcomes Research 2011, 3:55-61

Published Date: 14 March 2011

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

Giorgio L Colombo, Giovanni B Gaeta, Mauro Viganò, et al

ClinicoEconomics and Outcomes Research 2011, 3:37-46

Published Date: 15 February 2011

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy

Giorgio L Colombo, Sergio Di Matteo, Ketty Peris, Maria Concetta Fargnoli, et al.

ClinicoEconomics and Outcomes Research 2009, 1:53-59

Published Date: 15 October 2009

Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis

V Nicosia, Giorgio Colombo, M Consentino, S Di Matteo, F Mika, et al

Therapeutics and Clinical Risk Management 2008, 4:1105-1110

Published Date: 10 October 2008

Moderate and severe plaque psoriasis: cost-of-illness study in Italy

GL Colombo, GF Altomare, K Peris, P Martini, G Quarta

Therapeutics and Clinical Risk Management 2008, 4:559-568

Published Date: 11 April 2008

Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy

Giorgio L Colombo, Mauro Caruggi, Chiara Ottolini, Aldo P Maggioni

Vascular Health and Risk Management 2008, 4:223-234

Published Date: 8 February 2008

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010